Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial

American Journal of Obstetrics and Gynecology

Volumn 216, Issue 4, 2017, Pages 420.e1-420.e9

  Nanovskaya, Tatiana N ^a   Oncken, Cheryl ^b   Fokina, Valentina M ^a   Feinn, Richard S ^c   Clark, Shannon M ^a   West, Holly ^a   Jain, Sunil K ^a   Ahmed, Mahmoud S ^a   Hankins, Gary D V ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c Quinnipiac University   (United States)

Author keywords

bupropion sustained release; pregnancy; smoking cessation

Indexed keywords

AMFEBUTAMONE; CARBON MONOXIDE; COTININE; PLACEBO; ANTIDEPRESSANT AGENT; CARBON DIOXIDE; DELAYED RELEASE FORMULATION;

ADOLESCENT; AGE; ANXIETY; ANXIETY DISORDER; ARTICLE; BEHAVIOR THERAPY; BLOOD PH; CLINICAL ARTICLE; CONTROLLED STUDY; COUNSELING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG URINE LEVEL; EXPIRED AIR; FEMALE; HEADACHE; HUMAN; MATERNAL AGE; MATERNAL EXPOSURE; MATERNAL SMOKING; MEDICAL HISTORY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PATIENT COUNSELING; PERSONALIZED MEDICINE; PILOT STUDY; PREECLAMPSIA; PREGNANT WOMAN; PREMATURE LABOR; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RHINORRHEA; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SMOKING CESSATION PROGRAM; SMOKING HABIT; SUSTAINED DRUG RELEASE; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; WITHDRAWAL SYNDROME; XEROSTOMIA; ADULT; BREATH ANALYSIS; DELAYED RELEASE FORMULATION; EXHALATION; METABOLISM; PREGNANCY; PROCEDURES; SUBSTANCE WITHDRAWAL SYNDROME; URINE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BREATH TESTS; BUPROPION; CARBON DIOXIDE; COTININE; COUNSELING; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; EXHALATION; FEMALE; HUMANS; PREGNANCY; PROSPECTIVE STUDIES; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 85016330420     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2016.11.1036     Document Type: Article

References (32)

1. 1 Patnode, C.P., Henderson, J.T., Thompson, J.H., Senger, C.A., Fortmann, S.P., Whitlock, E.P., Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the US Preventive Services Task Force. Evidence synthesis no. 134. AHRQ publication no. 14-05200-EF-1. 2015, Agency for Healthcare Research and Quality, Rockville (MD).
2. 2 Fiore, M.C., Jaén, C.R., Baker, T.B., et al. Treating tobacco use and dependence: 2008 update. US Public Health Service Clinical Practice Guideline Executive Summary. Respir Care 53 (2008), 1217–1222.
3. 3 Lumley, J., Oliver, S.S., Chamberlain, C., Oakley, L., Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev, 2004, CD001055.
4. 4 Raupach, T., van Schayck, C.P., Pharmacotherapy for smoking cessation: current advances and research topics. CNS Drugs 25 (2011), 371–382.
5. 5 Chan, B., Einarson, A., Koren, G., Effectiveness of bupropion for smoking cessation during pregnancy. J Addict Dis 24 (2005), 19–23.
6. 6 Stout, R.L., Wirtz, P.W., Carbonari, J.P., Del Boca, F.K., Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol Suppl 12 (1994), 70–75.
7. 7 Rollnick, S., Butler, C.C., Stott, N., Helping smokers make decisions: the enhancement of brief intervention for general medical practice. Patient Educ Couns 31 (1997), 191–203.
8. 8 Rollnick, S., Heather, N., Gold, R., Hall, W., Development of a short ‘readiness to change’ questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict 87 (1992), 743–754.
9. 9 Dornelas, E.A., Magnavita, J., Beazoglou, T., et al. Efficacy and cost-effectiveness of a clinic-based counseling intervention tested in an ethnically diverse sample of pregnant smokers. Patient Educ Couns 64 (2006), 342–349.
10. 10 Berg, C.J., Park, E.R., Chang, Y., Rigotti, N.A., Is concern about post-cessation weight gain a barrier to smoking cessation among pregnant women?. Nicotine Tob Res 10 (2008), 1159–1163.
11. 11 Fucito, L.M., Toll, B.A., Salovey, P., O'Malley, S.S., Beliefs and attitudes about bupropion: implications for medication adherence and smoking cessation treatment. Psychol Addict Behav 23 (2009), 373–379.
12. 12 Heatherton, T.F., Kozlowski, L.T., Frecker, R.C., Fagerström, K.O., The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 86 (1991), 1119–1127.
13. 13 Hughes, J., Hatsukami, D.K., Errors in using tobacco withdrawal scale. Tob Control 7 (1998), 92–93.
14. 14 Spitzer, R.L., Kroenke, K., Williams, J.B., Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 282 (1999), 1737–1744.
15. 15 Bailey, B.A., Using expired air carbon monoxide to determine smoking status during pregnancy: preliminary identification of an appropriately sensitive and specific cut-point. Addict Behav 38 (2013), 2547–2550.
16. 16 Higgins, S.T., Heil, S.H., Badger, G.J., et al. Biochemical verification of smoking status in pregnant and recently postpartum women. Exp Clin Psychopharmacol 15 (2007), 58–66.
17. 17 Aurrekoetxea, J.J., Murcia, M., Rebagliato, M., et al. Determinants of self-reported smoking and misclassification during pregnancy, and analysis of optimal cut-off points for urinary cotinine: a cross-sectional study. BMJ Open, 3, 2013.
18. 18 Stragierowicz, J., Mikołajewska, K., Zawadzka-Stolarz, M., Polańska, K., Ligocka, D., Estimation of cutoff values of cotinine in urine and saliva for pregnant women in Poland. Biomed Res Int, 2013, 2013, 386784.
19. 19 Food and Drug Administration. Guidance for industry, bio-analytical method validation. Food and Drug Administration, Center for Drug Evaluation and Research, May 2011. Available at: http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry. Accessed December 29, 2016.
20. 20 Fokina, V.M., Wang, X., Ahmed, M., Oncken, C., Hankins, G.D.V., Nanovskaya, T.N., Determination of cotinine in the urine of pregnant patients enrolled in a clinical trial for the use of bupropion sustained release as an aid for smoking cessation. Drug and Alcohol Dependence, 146, 2015, e280.
21. 21 Petersen, G.O., Leite, C.E., Chatkin, J.M., Thiesen, F.V., Cotinine as a biomarker of tobacco exposure: development of a HPLC method and comparison of matrices. J Sep Sci 33 (2010), 516–521.
22. 22 Wang, X., Abdelrahman, D.R., Fokina, V.M., Hankins, G.D., Ahmed, M.S., Nanovskaya, T.N., Metabolism of bupropion by baboon hepatic and placental microsomes. Biochem Pharmacol 82 (2011), 295–303.
23. 23 Fokina, V.M., Xu, M., Rytting, E., et al. Pharmacokinetics of bupropion and its pharmacologically active metabolites in pregnancy. Drug Metab Dispos 44 (2016), 1832–1838.
24. 24 Oncken, C., Campbell, W., Chan, G., Hatsukami, D., Kranzler, H.R., Effects of nicotine patch or nasal spray on nicotine and cotinine concentrations in pregnant smokers. J Matern Fetal Neonatal Med 22 (2009), 751–758.
25. 25 Hurt, R.D., Sachs, D.P., Glover, E.D., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337 (1997), 1195–1202.
26. 26 Oncken, C.A., Kranzler, H.R., Pharmacotherapies to enhance smoking cessation during pregnancy. Drug Alcohol Rev 22 (2003), 191–202.
27. 27 Croft, H., Houser, T.L., Jamerson, B.D., et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther 24 (2002), 662–672.
28. 28 Hays, J.T., Ebbert, J.O., Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits. CNS Drugs 17 (2003), 71–83.
29. 29 Palmsten, K., Setoguchi, S., Margulis, A.V., Patrick, A.R., Hernández-Díaz, S., Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants?. Am J Epidemiol 175 (2012), 988–997.
30. 30 De Vera, M.A., Bérard, A., Antidepressant use during pregnancy and the risk of pregnancy-induced hypertension. Br J Clin Pharmacol 74 (2012), 362–369.
31. 31 Palmsten, K., Huybrechts, K.F., Michels, K.B., et al. Antidepressant use and risk for preeclampsia. Epidemiology 24 (2013), 682–691.
32. 32 Coleman, T., Chamberlain, C., Davey, M.A., Cooper, S.E., Leonardi-Bee, J., Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev, 2015, CD010078.